journal article·2026-03-20Open access

Advanced Studies in Molecular and Metabolic Mechanisms of Diabetes: Pathogenic Crosstalk, Biomarkers, and Translational Therapeutics

Iliyana Sazdova, Hristo Gagov, Nikola Hadzi-Petrushev, Marina Konaktchieva, Rossitza Konakchieva, Mitko Mladenov

Applied Sciences· Volume 16· Issue 6

Abstract

Diabetes mellitus is a rapidly escalating worldwide health issue that involves intricate molecular, metabolic, and systemic dysregulation. In addition to hyperglycemia, disease pathogenesis involves β-cell dysfunction, insulin resistance, mitochondrial dysfunction, endoplasmic reticulum stress (ER stress), redox imbalance, lipotoxicity, chronic inflammation, and inappropriate epigenetic modifications. New evidence also emphasizes the participation of mechanotransduction, ion channel signaling, circadian regulation, and organ cross-talk among the pancreas, liver, adipose tissue, skeletal muscle, heart, brain, and gut in modulating disease heterogeneity and progression. This review highlights updates of molecular mechanisms in diabetes, focusing on the β-cell response to stress, the AMPK–Sirtuin 1 (or PGC-1α) signaling pathway, mitochondrial quality control, mechanosensitive ion channels, immunometabolic crosstalk, and epigenetic regulation. We consider the increasing importance of multi-omics methods for early identification of pathogenic signatures and integration of artificial intelligence to enable precision stratification and therapeutic tailoring. Finally, we highlight novel experimental and translational tools, such as iPSC-derived β-cells or organoids, CRISPR-based gene editing, sophisticated metabolic imaging, and electrophysiology. Taken together, this review shifts the paradigm of diabetes as a system-level network disease and emphasizes the importance of data-driven multi-target strategies for prevention and reduction in long-term complications.
Source: crossref · Quality: baseline

Research context

OpenAlex topics: Pancreatic function and diabetes · Adipose Tissue and Metabolism · Metabolism, Diabetes, and Cancer

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Department of Animal and Human Physiology, Faculty of Biology, Sofia University “St. Kliment Ohridski”, 1164 Sofia, Bulgaria

Institute of Biology, Faculty of Natural Sciences and Mathematics, Ss. Cyril and Methodius University, 1000 Skopje, North Macedonia

Gastroenterology Department, Military Medical Academy, Sofia Center, Ul. “Sveti Georgi Sofiyski” 3, 1606 Sofia, Bulgaria

Department of Cell and Developmental Biology, Faculty of Biology, Sofia University “St. Kliment Ohridski”, 1164 Sofia, Bulgaria

Department of Fundamental and Applied Physiology, Russian State Medical University, 117997 Moscow, Russia

Funding

Ministry of Education and Science of Bulgaria

References (100+)

Show source-provided references
1. IDF Diabetes Atlas 11th Edition 2025: Global Prevalence and Projections for 205010.1093/ndt/gfaf177 ↗
2. GBD 2021 Diabetes Collaborators (2023). Global, Regional, and National Burden of Diabetes from 1990 to 2021, with Projections of Prevalence to 2050: A Systematic Analysis for the Global Burden of Disease Study 2021. Lancet, 402, 203–234.
3. World Health Organization (2024). Urgent Action Needed as Global Diabetes Cases Increase Four-Fold over Past Decades, WHO News Release.
4. Zhang, N., Qu, X., and Kang, L. (2025). Global, Regional and National Burden of Diabetes Mellitus Type 2 Attributable to Low Physical Activity from 1990 to 2021 and Projections to 2050: A Finding from the Global Burden of Disease Study 2021. Front. Clin. Diabetes Healthc., 6.10.3389/fcdhc.2025.1606330 ↗
5. Type 2 Diabetes Mellitus in Adults: Pathogenesis, Prevention and Therapy10.1038/s41392-024-01951-9 ↗
6. The Role of the Beta Cell in Type 2 Diabetes: New Findings from the Last 5 Years10.1007/s00125-025-06499-z ↗
7. A Review on Latent Autoimmune Diabetes in Adults
8. Adult-Onset Autoimmune Diabetes in 2020: An Update10.1016/j.maturitas.2020.04.014 ↗
9. Maturity Onset Diabetes of the Young (MODY)10.1002/dme.1996.13.s6.90 ↗
10. Maturity Onset Diabetes of the Young and Beyond: The Changing Face of Single-Gene Diabetes10.1093/ejendo/lvaf172 ↗
11. Double Diabetes: A Converging Metabolic and Autoimmune Disorder Redefining the Classification and Management of Diabetes
12. Double Diabetes—When Type 1 Diabetes Meets Type 2 Diabetes: Definition, Pathogenesis and Recognition10.1186/s12933-024-02145-x ↗
13. Unmet Needs in the Treatment of Type 1 Diabetes: Why Is It So Difficult to Achieve an Improvement in Metabolic Control?10.1038/s41387-024-00319-w ↗
14. Li, Y., Miao, Y., Feng, Q., Zhu, W., Chen, Y., Kang, Q., Wang, Z., Lu, F., and Zhang, Q. (2024). Mitochondrial Dysfunction and Onset of Type 2 Diabetes: A Multi-Omics Mendelian Randomization and Colocalization Study. Front. Endocrinol., 15.10.3389/fendo.2024.1401531 ↗
15. Mitochondrial Quality Control in Diabetes Mellitus and Complications: Molecular Mechanisms and Therapeutic Strategies10.1038/s41419-025-07936-y ↗
16. Molecular Aspects of Mitochondrial Dysfunction in Diabetes, Pearson and Kearns–Sayre Syndromes, and Neurodegenerative Disorders10.2147/IJGM.S539967 ↗
17. Iheagwam, F.N., Joseph, A.J., Adedoyin, E.D., Iheagwam, O.T., and Ejoh, S.A. (2025). Mitochondrial Dysfunction in Diabetes: Shedding Light on a Widespread Oversight. Pathophysiology, 32.10.3390/pathophysiology32010009 ↗
18. PGC-1α, Inflammation, and Oxidative Stress: An Integrative View in Metabolism
19. AMPK/SIRT1/PGC-1α Signaling Pathway: Molecular Mechanisms and Targeted Strategies from Energy Homeostasis Regulation to Disease Therapy10.1111/cns.70657 ↗
20. Energy Metabolism in Health and Diseases10.1038/s41392-025-02141-x ↗
21. Shrestha, N., De Franco, E., Arvan, P., and Cnop, M. (2021). Pathological β-Cell Endoplasmic Reticulum Stress in Type 2 Diabetes: Current Evidence. Front. Endocrinol., 12.10.3389/fendo.2021.650158 ↗
22. The Role of Endoplasmic Reticulum Stress in Type 2 Diabetes Mellitus Mechanisms and Impact on Islet Function10.7717/peerj.19192 ↗
23. Vilas-Boas, E.A., Almeida, D.C., Roma, L.P., Ortis, F., and Carpinelli, A.R. (2021). Lipotoxicity and β-Cell Failure in Type 2 Diabetes: Oxidative Stress Linked to NADPH Oxidase and ER Stress. Cells, 10.10.3390/cells10123328 ↗
24. Thomas, P., Gallagher, M.T., and Xavier, G.D.S. (2023). Beta Cell Lipotoxicity in the Development of Type 2 Diabetes: The Need for Species-Specific Understanding. Front. Endocrinol., 14.10.3389/fendo.2023.1275835 ↗
25. Lipotoxicity Induces β-Cell Small Extracellular Vesicle-Mediated β-Cell Dysfunction in Male Mice10.1210/endocr/bqaf067 ↗
26. Dhieb, D., Mustafa, D., Hassiba, M., Alasmar, M., Elsayed, M.H., Musa, A., Zirie, M., and Bastaki, K. (2025). Harnessing Pharmacomultiomics for Precision Medicine in Diabetes: A Comprehensive Review. Biomedicines, 13.10.3390/biomedicines13020447 ↗
27. Anwardeen, N.R., Naja, K., and Elrayess, M.A. (2024). Advancements in Precision Medicine: Multi-Omics Approach for Tailored Metformin Treatment in Type 2 Diabetes. Front. Pharmacol., 15.10.3389/fphar.2024.1506767 ↗
28. Genomics and Multiomics in the Age of Precision Medicine10.1038/s41390-025-04021-0 ↗
29. Artificial Intelligence and Multi-Omics in Pharmacogenomics: A New Era of Precision Medicine10.1016/j.mcpdig.2025.100246 ↗
30. Illuminating Diabetes via Multi-Omics: Unraveling Disease Mechanisms and Advancing Personalized Therapy10.4239/wjd.v16.i7.106218 ↗
31. Transparent reporting of a multivariable prediction model for individual prognosis or diagnosis (TRIPOD)10.1161/CIRCULATIONAHA.114.014508 ↗
32. PROBAST+AI: An updated quality, risk of bias, and applicability assessment tool for prediction models using regression or artificial intelligence methods10.1136/bmj-2024-082505 ↗
33. Big data and machine learning in health care10.1001/jama.2017.18391 ↗
34. Guidelines for artificial intelligence in medicine: Literature review and content analysis of frameworks10.2196/36823 ↗
35. Semaglutide and cardiovascular outcomes in obesity without diabetes10.1056/NEJMoa2307563 ↗
36. Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes10.1056/NEJMoa2025845 ↗
37. Developments in stem cell-derived islet replacement therapy for treating type 1 diabetes10.1016/j.stem.2023.04.002 ↗
38. Vertex Pharmaceuticals Incorporated (2025, August 01). A Safety, Tolerability, and Efficacy Study of VX-880 in Participants with Type 1 Diabetes. ClinicalTrials.gov. Identifier: NCT04786262, Available online: https://clinicaltrials.gov/study/NCT04786262.
39. Scoping studies: Towards a methodological framework10.1080/1364557032000119616 ↗
40. Guidance for conducting systematic scoping reviews10.1097/XEB.0000000000000050 ↗
41. The PRISMA 2020 statement: An updated guideline for reporting systematic reviews10.1136/bmj.n71 ↗
42. A typology of reviews: An analysis of 14 review types and associated methodologies10.1111/j.1471-1842.2009.00848.x ↗
43. Pancreatic β-cell dysfunction in type 2 diabetes: Implications of inflammation and oxidative stress10.4239/wjd.v14.i3.130 ↗
44. Molecular and inflammatory etiologies of β-cell dysfunction in type 1 diabetes10.1152/physiol.00008.2025 ↗
45. An accomplice more than a mere victim: The impact of β-cell ER stress on type 1 diabetes pathogenesis10.1016/j.molmet.2021.101365 ↗
46. Aberrant islet unfolded protein response in type 2 diabetes10.1038/srep04054 ↗
47. Endoplasmic reticulum stress and dysregulated autophagy in human pancreatic beta cells10.4093/dmj.2022.0070 ↗
48. Therapeutic opportunities for pancreatic β-cell ER stress in diabetes mellitus10.1038/s41574-021-00510-4 ↗
49. Dobson, J.R., and Jacobson, D.A. (2024). Disrupted endoplasmic reticulum Ca2+ handling: A harbinger of β-cell failure. Biology, 13.10.3390/biology13060379 ↗
50. Zaher, A., and Stephens, S.B. (2025). Breaking the feedback loop of β-cell failure: Insight into the pancreatic β-cell’s ER–mitochondria redox balance. Cells, 14.10.3390/cells14060399 ↗
51. Inside the β cell: Molecular stress response pathways in diabetes pathogenesis10.1210/endocr/bqac184 ↗
52. Yang, Y., and Cheng, H. (2024). Emerging roles of ncRNAs in type 2 diabetes mellitus: From mechanisms to drug discovery. Biomolecules, 14.10.3390/biom14111364 ↗
53. A three-layer perspective on miRNA regulation in β-cell inflammation10.1016/j.tem.2024.10.002 ↗
54. Chi, T., Lin, J., Wang, M., Zhao, Y., Liao, Z., and Wei, P. (2021). Non-coding RNA as biomarkers for type 2 diabetes development and clinical management. Front. Endocrinol., 12.10.3389/fendo.2021.630032 ↗
55. Circulating miRNA as potential biomarkers for diabetes mellitus type 2: Should we focus on searching for sex differences?10.1007/s13353-021-00678-5 ↗
56. Li, L., Wu, Y.-Q., and Yang, J.-E. (2025). Stress-related lncRNAs and their roles in diabetes and diabetic complications. Int. J. Mol. Sci., 26.10.3390/ijms26052194 ↗
57. Ke, L., Cao, Y., Lu, Z., and Hallajzadeh, J. (2024). Advances in different adult stem cell-derived exosomal non-coding RNAs for the treatment of neurological disorders: A narrative review. Front. Cell Dev. Biol., 12.10.3389/fcell.2024.1459246 ↗
58. Exosomes derived from mesenchymal stem cells in diabetes and diabetic complications10.1038/s41419-024-06659-w ↗
59. The miR-200 family in type 2 diabetes: Therapeutic and biomarker perspectives10.1016/j.jdiacomp.2025.109211 ↗
60. Dinić, S., Arambašić Jovanović, J., Uskoković, A., Mihailović, M., Grdović, N., Tolić, A., Rajić, J., Đorđević, M., and Vidaković, M. (2022). Oxidative stress-mediated beta cell death and dysfunction as a target for diabetes management. Front. Endocrinol., 13.10.3389/fendo.2022.1006376 ↗
61. Role of oxidative stress in prediabetes development
62. Oxidative stress in diabetes mellitus and its complications: From pathophysiology to therapeutic strategies10.1097/CM9.0000000000003230 ↗
63. Overcoming β-cell dysfunction in type 2 diabetes mellitus: CD36 inhibition and antioxidant system10.4093/dmj.2024.0796 ↗
64. Redox regulation of UPR signaling and mitochondrial ER contact sites10.1007/s00018-024-05286-0 ↗
65. Reversing pancreatic β-cell dedifferentiation in the treatment of type 2 diabetes10.1038/s12276-023-01043-8 ↗
66. Rosenbaum Emir, T.L. (2017). The role of TRP channels in the pancreatic beta-cell. Neurobiology of TRP Channels, Taylor & Francis. Chapter 12.
67. Liu, Y., Lyu, Y., and Wang, H. (2022). TRP channels as molecular targets to relieve endocrine-related diseases. Front. Mol. Biosci., 9.10.3389/fmolb.2022.895814 ↗
68. TRPM7 is a crucial regulator of pancreatic endocrine development and high-fat-diet-induced β-cell proliferation10.1242/dev.194928 ↗
69. TRPM7 kinase is required for insulin production and compensatory islet responses during obesity10.1172/jci.insight.163397 ↗
70. A critical role of the mechanosensor PIEZO1 in glucose-induced insulin secretion in pancreatic β-cells10.1038/s41467-022-31103-y ↗
71. Piezo1 channel activation mimics high glucose as a stimulator of insulin release10.1038/s41598-019-51518-w ↗
72. Extracellular matrix stiffness mediates insulin secretion in pancreatic islets via mechanosensitive Piezo1 channel regulated Ca2+ dynamics10.1016/j.mbplus.2024.100148 ↗
73. Galli, A., Algerta, M., Marciani, P., Schulte, C., Lenardi, C., Milani, P., Maffioli, E., Tedeschi, G., and Perego, C. (2020). Shaping pancreatic β-cell differentiation and functioning: The influence of mechanotransduction. Cells, 9.10.3390/cells9020413 ↗
74. Matrix stiffness and its influence on pancreatic diseases10.1016/j.bbcan.2021.188583 ↗
75. The stiffness of extracellular matrix in regulating cellular metabolism10.1152/ajpcell.00913.2024 ↗
76. KATP channels and the metabolic regulation of insulin secretion in health and disease: The 2022 Banting Medal for Scientific Achievement Award Lecture10.2337/dbi22-0030 ↗
77. Rodríguez-Rivera, N.S., and Barrera-Oviedo, D. (2024). Exploring the pathophysiology of ATP-dependent potassium channels in insulin resistance. Int. J. Mol. Sci., 25.10.20944/preprints202403.0502.v1 ↗
78. Current understanding of KATP channels in neonatal diseases: Focus on insulin secretion disorders10.1038/aps.2011.57 ↗
79. A plasma membrane-associated glycolytic metabolon is functionally coupled to KATP channels in pancreatic α and β cells from humans and mice10.1016/j.celrep.2023.112394 ↗
80. The AMPK–SIRT1 axis: Redefining type 2 diabetes mellitus management10.1016/j.rechem.2025.102139 ↗
81. Guan, G., Chen, Y., and Dong, Y. (2025). Unraveling the AMPK–SIRT1–FOXO pathway: The in-depth analysis and breakthrough prospects of oxidative stress-induced diseases. Antioxidants, 14.10.3390/antiox14010070 ↗
82. Pancreatic β-cells, diabetes and autophagy10.1080/07435800.2024.2413064 ↗
83. New developments in AMPK and mTORC1 cross-talk10.1042/EBC20240007 ↗
84. From omics to AI—Mapping the pathogenic pathways in type 2 diabetes10.1002/1873-3468.70115 ↗
85. Kosgei, V.J., Coelho, D., Guéant-Rodriguez, R.M., and Guéant, J.-L. (2020). Sirt1-PPARS cross-talk in complex metabolic diseases and inherited disorders of the one carbon metabolism. Cells, 9.10.3390/cells9081882 ↗
86. Kiełbowski, K., Bakinowska, E., and Pawlik, A. (2025). Epigenetics plays a role in the pathogenesis and treatment of diabetes. Genes, 16.10.3390/genes16070769 ↗
87. Targeting the epigenetic marks in type 2 diabetes mellitus: Will epigenetic therapy be a valuable adjunct to pharmacotherapy?10.2147/DMSO.S479077 ↗
88. The impact of epigenetics on the pathophysiology of type 2 diabetes and associated nephropathic complications10.4103/ijem.ijem_43_24 ↗
89. Multiomics integration of epigenetics, proteomics, and metabolomics identifies putative drug targets and improves early prediction for diabetes10.2337/db25-0354 ↗
90. Liu, Y., Lei, Y., Dai, Z., Luo, C., Gong, Q., Li, Y., Xu, Y., and Huang, W. (2025). Trained immunity: Novel perspectives in diabetes and associated complications. Front. Immunol., 16.10.3389/fimmu.2025.1613602 ↗
91. Nițulescu, I.M., Ciulei, G., Cozma, A., Procopciuc, L.M., and Orășan, O.H. (2023). From innate immunity to metabolic disorder: A review of the NLRP3 inflammasome in diabetes mellitus. J. Clin. Med., 12.10.3390/jcm12186022 ↗
92. Karamitsos, K., Oikonomou, E., Theofilis, P., Ikonomidis, I., Kassi, E., Lambadiari, V., Gialafos, E., Tsatsaragkou, A., Mystakidi, V.-C., and Zisimos, K. (2025). The role of NLRP3 inflammasome in type 2 diabetes mellitus and its macrovascular complications. J. Clin. Med., 14.10.3390/jcm14134606 ↗
93. Targeting the NLRP3 inflammasome–IL-1β pathway in type 2 diabetes and obesity10.1007/s00125-024-06306-1 ↗
94. Chong, S., Lin, M., Chong, D., Jensen, S., and Lau, N.S. (2025). A systematic review on gut microbiota in type 2 diabetes mellitus. Front. Endocrinol., 15.10.3389/fendo.2024.1486793 ↗
95. The gut microbiota and diabetes: Research, translation, and clinical applications—2023 Expert Forum
96. The gut microbiota pathway mechanisms of diabetes10.1186/s13568-023-01520-3 ↗
97. Gut microbiota-derived short-chain fatty acids and their role in human health and disease10.1038/s41579-025-01183-w ↗
98. Gut-liver axis in diabetes: Mechanisms and therapeutic opportunities10.3748/wjg.v31.i29.109090 ↗
99. Seo, H., Park, J.-H., Hwang, J.-T., Choi, H.-K., Park, S.-H., and Lee, J. (2023). Epigenetic profiling of type 2 diabetes mellitus: An epigenome-wide association study. Genes, 14.10.3390/genes14122207 ↗
100. Longitudinal association between DNA methylation and type 2 diabetes: Findings from the KORA F4/FF4 study10.1186/s12933-024-02558-8 ↗